{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:19:02Z","timestamp":1793319542326,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jacc.2024.09.010","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T10:04:44Z","timestamp":1736157884000},"page":"58-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of Systemic Thromboxane Generation With Risk of Developing Heart\u00a0Failure"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8607-4569","authenticated-orcid":false,"given":"Jeffrey J.","family":"Rade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari S.","family":"Kronsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Kickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramachandran S.","family":"Vasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Xanthakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6993-9396","authenticated-orcid":false,"given":"Matthew G.","family":"Nayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jacc.2024.09.010_bib1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1161\/CIRCULATIONAHA.108.768283","article-title":"Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk","volume":"118","author":"Eikelboom","year":"2008","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacc.2024.09.010_bib2","article-title":"Differential impact of serial measurement of nonplatelet thromboxane generation on long-term outcome after cardiac surgery","volume":"6","author":"Kakouros","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jacc.2024.09.010_bib3","first-page":"653","article-title":"Prognostic value of urinary 11-dehydro-thromboxane B(2) for mortality: a cohort study of stable coronary artery disease patients treated with aspirin","volume":"92","author":"Vasudevan","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.jacc.2024.09.010_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jacc.2022.04.034","article-title":"Association of thromboxane generation with survival in aspirin users and nonusers","volume":"80","author":"Rade","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2024.09.010_bib5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cellsig.2003.10.008","article-title":"Cell signalling through thromboxane A2 receptors","volume":"16","author":"Huang","year":"2004","journal-title":"Cell Signal"},{"issue":"25","key":"10.1016\/j.jacc.2024.09.010_bib6","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","article-title":"Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance","volume":"113","author":"Frelinger","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.09.010_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12967-016-0827-7","article-title":"The lack of aspirin resistance in patients with coronary artery disease","volume":"14","author":"Homorodi","year":"2016","journal-title":"J\u00a0Transl Med"},{"issue":"8","key":"10.1016\/j.jacc.2024.09.010_bib8","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"Patrignani","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"19","key":"10.1016\/j.jacc.2024.09.010_bib9","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.667584","article-title":"Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1","volume":"115","author":"Faraday","year":"2007","journal-title":"Circulation"},{"issue":"2B","key":"10.1016\/j.jacc.2024.09.010_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9343(86)90905-8","article-title":"Measurement of renal and non-renal eicosanoid synthesis","volume":"81","author":"Catella","year":"1986","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.jacc.2024.09.010_bib11","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1097\/00003246-199110000-00012","article-title":"Inhibition of thromboxane synthesis reduces endotoxin-induced right ventricular failure in sheep","volume":"19","author":"Redl","year":"1991","journal-title":"Crit Care Med"},{"issue":"7","key":"10.1016\/j.jacc.2024.09.010_bib12","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.bjp.0704416","article-title":"Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan","volume":"134","author":"Katugampola","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jacc.2024.09.010_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1086\/686140","article-title":"Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload","volume":"6","author":"West","year":"2016","journal-title":"Pulm Circ"},{"issue":"4","key":"10.1016\/j.jacc.2024.09.010_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1748-1716.2012.02437.x","article-title":"Cyclooxygenase-2 inhibition and thromboxane A(2) receptor antagonism attenuate hypoxic pulmonary vasoconstriction in a porcine model","volume":"205","author":"Kylhammar","year":"2012","journal-title":"Acta Physiol (Oxf)"},{"issue":"21","key":"10.1016\/j.jacc.2024.09.010_bib15","article-title":"Antagonism of the thromboxane-prostanoid receptor as a potential therapy for cardiomyopathy of muscular dystrophy","volume":"8","author":"West","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacc.2024.09.010_bib16","article-title":"Risk factors for non-platelet thromboxane generation after coronary artery bypass graft surgery","volume":"5","author":"Kakouros","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacc.2024.09.010_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0002-8703(97)70253-9","article-title":"Increased renal formation of thromboxane A2 and prostaglandin F2 alpha in heart failure","volume":"133","author":"Castellani","year":"1997","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.jacc.2024.09.010_bib18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1538-7836.2010.03820.x","article-title":"Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment","volume":"8","author":"Santilli","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jacc.2024.09.010_bib19","doi-asserted-by":"crossref","first-page":"H248","DOI":"10.1152\/ajpheart.00212.2022","article-title":"Nonplatelet thromboxane generation is associated with impaired cardiovascular performance and mortality in heart failure","volume":"323","author":"Hariri","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10","key":"10.1016\/j.jacc.2024.09.010_bib20","article-title":"Distinct aspects of left ventricular mechanical function are differentially associated with cardiovascular outcomes and all-cause mortality in the community","volume":"4","author":"Cheng","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.jacc.2024.09.010_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCHEARTFAILURE.112.972828","article-title":"Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction","volume":"6","author":"Ho","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2024.09.010_bib22","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","article-title":"Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute","volume":"119","author":"Lee","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacc.2024.09.010_bib23","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1111\/jth.12026","article-title":"Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk","volume":"10","author":"Olson","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"19","key":"10.1016\/j.jacc.2024.09.010_bib24","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jacc.2024.09.010_bib25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.ATV.0000058402.34138.11","article-title":"Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study","volume":"23","author":"Keaney","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jacc.2024.09.010_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2013.01.019","article-title":"Clinical correlates of change in inflammatory biomarkers: the Framingham Heart Study","volume":"228","author":"Fontes","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2024.09.010_bib27","unstructured":"Framingham Heart Study. FHS Dataset Inventory for Public Viewing. Accessed October 8, 2024. https:\/\/wwwapp.bumc.bu.edu\/FHSresapp\/Public\/DataSetList"},{"issue":"4","key":"10.1016\/j.jacc.2024.09.010_bib28","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/clinchem\/hvae015","article-title":"Adjustment for renal function improves the prognostic performance of urinary thromboxane metabolites","volume":"70","author":"Barton","year":"2024","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2024.09.010_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"22","key":"10.1016\/j.jacc.2024.09.010_bib30","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1093\/eurheartj\/ehl305","article-title":"Platelets and heart failure","volume":"27","author":"Chung","year":"2006","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacc.2024.09.010_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1074248415609436","article-title":"A\u00a0central role for monocyte-platelet interactions in heart failure","volume":"21","author":"Glezeva","year":"2016","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"issue":"24","key":"10.1016\/j.jacc.2024.09.010_bib32","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ehj.2003.08.021","article-title":"The adhesion molecule P-selectin and cardiovascular disease","volume":"24","author":"Blann","year":"2003","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.jacc.2024.09.010_bib33","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jacc.2007.12.048","article-title":"Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study","volume":"51","author":"Bahrami","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.010_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCHEARTFAILURE.108.785485","article-title":"Metabolic syndrome, inflammation, and incident heart failure in the elderly: the Cardiovascular Health Study","volume":"1","author":"Suzuki","year":"2008","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10.1016\/j.jacc.2024.09.010_bib35","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","article-title":"Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study","volume":"107","author":"Vasan","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacc.2024.09.010_bib36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamacardio.2017.4987","article-title":"Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction","volume":"3","author":"de Boer","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacc.2024.09.010_bib37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.annepidem.2011.06.005","article-title":"White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) study","volume":"21","author":"Bekwelem","year":"2011","journal-title":"Ann Epidemiol"},{"issue":"3","key":"10.1016\/j.jacc.2024.09.010_bib38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ahj.2006.02.023","article-title":"C-reactive protein and risk of heart failure. The Rotterdam Study","volume":"152","author":"Kardys","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2024.09.010_bib39","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jacc.2023.05.035","article-title":"C-reactive protein and risk of incident heart failure in patients with cardiovascular disease","volume":"82","author":"Burger","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2024.09.010_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2016.10.022","article-title":"Oxidative stress reflected by increased F2-isoprostanes is associated with increasing urinary 11-dehydro thromboxane B2 levels in patients with coronary artery disease","volume":"148","author":"McCullough","year":"2016","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.jacc.2024.09.010_bib41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.thromres.2007.07.011","article-title":"Platelet adhesion in congestive heart failure","volume":"121","author":"Chung","year":"2008","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.jacc.2024.09.010_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.thromres.2007.01.003","article-title":"Platelet activation in acute, decompensated congestive heart failure","volume":"120","author":"Chung","year":"2007","journal-title":"Thromb Res"},{"issue":"38","key":"10.1016\/j.jacc.2024.09.010_bib43","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1093\/eurheartj\/ehv305","article-title":"Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications","volume":"36","author":"M\u00fcnzel","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacc.2024.09.010_bib44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejheart.2004.05.007","article-title":"Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha)","volume":"7","author":"Wolfram","year":"2005","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.jacc.2024.09.010_bib45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1179\/135100008X259204","article-title":"Markers of oxidative damage in chronic heart failure: role in disease progression","volume":"13","author":"Radovanovic","year":"2008","journal-title":"Redox Rep"},{"issue":"8","key":"10.1016\/j.jacc.2024.09.010_bib46","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/heart.89.8.871","article-title":"Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress","volume":"89","author":"Nonaka-Sarukawa","year":"2003","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.jacc.2024.09.010_bib47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ehf2.14617","article-title":"Causal relationship between aspirin consumption and heart failure: a Mendelian randomization study","volume":"11","author":"Cai","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2024.09.010_bib48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/ehf2.13688","article-title":"Heart Omics in Ageing Investigators. Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis","volume":"9","author":"Mujaj","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"2","key":"10.1016\/j.jacc.2024.09.010_bib49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jchf.2017.09.021","article-title":"Low-dose aspirin in heart failure not complicated by atrial fibrillation: a nationwide propensity-matched study","volume":"6","author":"Madelaire","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"25","key":"10.1016\/j.jacc.2024.09.010_bib50","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2021.06.058","article-title":"Race and\u00a0ethnicity in heart failure: JACC Focus Seminar 8\/9","volume":"78","author":"Pi\u00f1a","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724084626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724084626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T01:17:30Z","timestamp":1767748650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724084626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0735109724084626"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.09.010","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Systemic Thromboxane Generation With Risk of Developing Heart\u00a0Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}